Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction

J Med Chem. 2001 Mar 29;44(7):1025-7. doi: 10.1021/jm0155042.

Authors

G Yu¹, H J Mason, X Wu, J Wang, S Chong, G Dorough, A Henwood, R Pongrac, L Seliger, B He, D Normandin, L Adam, J Krupinski, J E Macor

Affiliation

¹ Discovery Chemistry, Drug Metabolism and Pharmacokinetics, Drug Safety, and Metabolic & Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, USA. [email protected]

PMID: 11297448
DOI: 10.1021/jm0155042

No abstract available

MeSH terms

3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors*
Administration, Oral
Animals
Cyclic Nucleotide Phosphodiesterases, Type 5
Dogs
Erectile Dysfunction / drug therapy
In Vitro Techniques
Male
Muscle Relaxation / drug effects
Muscle, Smooth / drug effects
Muscle, Smooth / physiology
Penis / drug effects
Penis / physiology
Phosphodiesterase Inhibitors / chemical synthesis*
Phosphodiesterase Inhibitors / chemistry
Phosphodiesterase Inhibitors / pharmacokinetics
Phosphodiesterase Inhibitors / pharmacology
Pyridines / chemical synthesis*
Pyridines / chemistry
Pyridines / pharmacokinetics
Pyridines / pharmacology
Rabbits
Rats
Structure-Activity Relationship

Substances

Phosphodiesterase Inhibitors
Pyridines
3',5'-Cyclic-GMP Phosphodiesterases
Cyclic Nucleotide Phosphodiesterases, Type 5
Pde5a protein, rat